Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Key takeaways from ASH 2020 in multiple myeloma

Thomas Martin • 10 Feb 2021
ASH 2020
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide
FORTE

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explores key takeaways from the recent ASH 2020 virtual meeting, including progression-free survival data using daratumumab, lenalidomide, and dexamethasone combination therapy in transplant ineligible patients with multiple myeloma, as well as results of the FORTE trial (NCT02203643) presented at ASH. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Thomas Martin

4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
2:57
Considerations for mitigating CAR-T resistance in multiple myeloma
Thomas Martin • 11 Sep 2023
4:14
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Thomas Martin • 11 Sep 2023
9:52
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin • 11 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals